NF1 and neoplasm: In this study, single-agent tovorafenib had little anti-proliferative effect in NF1-LOF tumor cell lines, yet the combination of pimasertib with either tovorafenib or TAK-632 exhibited synergy in NF1-LOF tumor models in vitro.